Physician profile
Anil Kumar Lamba
NPI 1225013238
$699.00
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $12.51 · 2021: $14.71 · 2022: $20.70 · 2023: $447 · 2024: $64.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lemaitre Vascular, INC. | $178.55 | 2023-2024 | Hydro Lemaitre Valvulotome, Trivex System, Artegraft Vascular Graft |
| Genentech USA, INC. | $142.02 | 2023 | Tecentriq |
| Takeda Pharmaceuticals U.S.A., INC. | $77.66 | 2023-2024 | Entyvio, Gattex |
| Allergan, INC. | $77.65 | 2019 | |
| Integra Lifesciences Corporation | $53.08 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Ardelyx, INC. | $29.05 | 2023 | Ibsrela |
| Csl Behring | $26.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.00 | 2019 | |
| Activ Surgical, INC. | $20.70 | 2022 | |
| Tela Bio, INC. | $16.67 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Kci USA, INC. | $14.71 | 2021 | |
| Monaghan Medical Corporation | $14.38 | 2023 | Aeroeclipse |
| Smith+Nephew, INC. | $12.81 | 2019 | |
| Thd America, INC. | $12.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Lamba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.